Alex Stojanovic is #hiring. Know anyone who might be interested?
Oncolyze
Biotechnology Research
New York City, NY 296 followers
Developing a class of therapeutics to treat cancer using a novel and potentially disruptive mechanism of action.
About us
Oncolyze is developing a disruptive technology for the treatment of cancer. Our novel approach uses a simple mechanism of action to selectively kill cancer cells and cancer stem cells while sparing normal cells. This provides a highly effective treatment with little to no side effects. Our lead drug candidate, OM-301, has two parts; the first attaches to a molecule that is present on the cell surface of more than 80% of cancer types we have assessed, but not on normal cells. When our drug attaches to this target, it uses it as an anchor; the second part then pokes holes in the cell membrane, causing extracellular liquid to rapidly enter, which in turn causes the cancer cell to burst. No known cancer drug uses such a mechanism, although many antibiotics kill bacteria in a similar way. Our initial therapeutic target is acute myelogenous leukemia (AML). Most AML patients relapse within 1 year of standard therapy, because it does not destroy cancer stem cells. As a result, AML has only a 25% 5-year survival rate. In contrast, OM-301 does destroy cancer stem cells, which has the potential to disrupt current medical treatment and fully cure AML. Recently, we showed that mice injected with AML cells taken directly from patients lived twice as long after receiving our drug. Following our proof of concept in AML, we expect to pursue development for patients with Multiple Myeloma and other blood and solid cancers.
- Website
-
http://www.oncolyze.com
External link for Oncolyze
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- New York City, NY
- Type
- Privately Held
- Specialties
- Oncology, Leukemia, and Myeloma
Locations
-
Primary
Get directions
New York City, NY 10017, US
Employees at Oncolyze
Updates
-
Wishing all our investors, partners, collaborators, advisors, employees, friends, and family a happy and healthy 2024! #happynewyear #holidayseason
-
-
Well deserved recognition!
Check out our latest Biotech Leader Spotlight: Please join us in recognizing Stanley T. Lewis, MD, MPH, Founder and Chief Executive Officer of A28 Therapeutics. Previously serving as Chief Medical Officer of Ansun Biopharma, Inc. Lewis is a proven leader in life sciences, with 25 years of experience in clinical research, drug development, patient care and teaching. #biotech #biotechnology #clinicalresearch #drugdevelopment #pharmaceuticals #leadership #biotechindustry #biotechinnovation
-
"Cancer may have started the fight, but I will finish it." Inspired by every fighter, we at Oncolyze are relentless in our research, especially with promising drugs like OM-301. We're committed to finishing this fight alongside you. This month is almost done, but let’s not stop; let's fight even stronger. Stand with Oncolyze and intensify the fight. #bloodcancerawarenessmonth Solidify your stand; delve deeper into Oncolyze's mission (https://www.oncolyze.com/) and support our groundbreaking work by purchasing shares here: https://lnkd.in/epVsHKTZ. You should read the Offering Circular (https://lnkd.in/ezWEQbuX) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #biotech #bloodcancerawareness #OM301 #cancer #cancerwarrior #cancerfighter #cancertreatment #oncolyze
-
"Research is to see what everybody else has seen, and to think what nobody else has thought." - Albert Szent-Györgyi. At Oncolyze, we're driven to redefine possibilities, pushing OM-301's boundaries, aiming for a world without blood cancer. #bloodcancerawarenessmonth Ignite this vision with us; learn more about Oncolyze and contribute to our mission by purchasing shares here: https://lnkd.in/epVsHKTZ. You should read the Offering Circular (https://lnkd.in/ezWEQbuX) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #biotech #bloodcancerawareness #OM301 #cancer #cancerwarrior #OncolyzeInnovation
Oncolyze
oncolyze.com
-
1.3 million people search for hope amidst blood cancer. At Oncolyze, every advancement, especially in OM-301, is for patients. We're dedicated to making a difference. Take a step closer to the hope we envision. This #BloodCancerAwarenessMonth discover more about Oncolyze and consider supporting our endeavors by purchasing shares here: https://lnkd.in/epVsHKTZ. You should read the Offering Circular (https://lnkd.in/ezWEQbuX) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #biotech #bloodcancerawareness #OM301 #cancer #cancerwarrior #cancersurvivors
Oncolyze
oncolyze.com
-
"The human spirit is stronger than anything that can happen to it.” ― C.C. Scott. To every blood cancer warrior: Your courage fuels our progress at Oncolyze, especially our work on OM-301. We stand with you now and always. Just this month, let’s say it OUT LOUD. #BloodCancerAwarenessMonth Further unite with us by exploring more about Oncolyze and how you can make an impact through share purchase here: https://lnkd.in/epVsHKTZ. You should read the Offering Circular (https://lnkd.in/ezWEQbuX) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #biotech #bloodcancerawareness #OM301 #cancer #cancerwarrior #cancersurvivors
Oncolyze
oncolyze.com
-
Every 3 minutes, someone is diagnosed with blood cancer. At Oncolyze, we see beyond statistics. We envision hope and the positive impact of our research, particularly with OM-301. Join us in visualizing a brighter future this #BloodCancerAwarenessMonth. Want to be a part of our vision? Learn more about Oncolyze and consider supporting our pursuit for new treatments by purchasing shares here: https://lnkd.in/epVsHKTZ You should read the Offering Circular (https://lnkd.in/ezWEQbuX) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #biotech #bloodcancerawareness #OM301
Oncolyze
oncolyze.com